Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development
Ella Day | June 30, 2025 | Appointment | Research and Development | Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics
Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and previously its chief scientific officer, Wills has played a central role in shaping Ochre’s approach to developing RNA-based therapies for chronic liver disease.
The appointment signals a new phase of growth for Ochre as it advances its lead candidates toward the clinic. With two significant partnerships already in place with pharma companies GSK and Boehringer Ingelheim, the company is progressing RNA therapeutics aimed at reversing fibrosis, cirrhosis and other late-stage liver conditions – diseases that have long lacked effective treatment options.
Wills brings two decades of experience in liver genomics. Throughout his career, he has focused on identifying the genetic drivers of chronic liver disease and designing therapeutic strategies to intervene before end-stage organ failure.
“Getting medicines to patients has been a deeply personal journey of 20 years in liver research,” said Wills. “We started Ochre almost six years ago with a simple mission: to rewrite the future for people living with chronic liver disease. I could not be more thrilled to now be steering our therapies towards the clinic.”
Chair of Ochre board, Eliot Forster, commented: “This is excellent news for Ochre, its investors and the future of liver disease treatment.”
Headquartered in Oxford, UK with research facilities in New York, US, and Taipei, Taiwan, Ochre Bio operates the world’s largest perfused liver lab and integrates AI with human tissue models to accelerate RNA drug discovery.
Ella Day
30/6/25
Related Content
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …
University of Southern Denmark pairs with Argobio to launch next-generation RNA company Inverna Therapeutics
The launch of new RNA company Inverna Therapeutics was announced today. Inerva Therapeutics begins with …
